Timothy Glidewell on CosMx – A Promise for Severe Aplastic Anemia
Timothy Glidewell, Spatial Regional Account Manager at Bruker Spatial, reposted from The National Institutes of Health on LinkedIn:
”The latest NCI update on an experimental therapy for severe aplastic anemia is an important signal for anyone thinking about bone marrow failure, immune dysregulation, and why only some patients respond to treatment.
To truly unravel these questions, we need to see how stem/progenitor cells, stromal support cells, and immune effectors are organized and interacting in situ.
That’s where CosMx™ Spatial Molecular Imager can help—enabling single-cell, subcellular, whole-transcriptome views of rare cell populations within the marrow niche.
These insights can support translational teams working to understand mechanisms of response and resistance in severe, immune-mediated diseases.
If you’re in the Bay Area and would like to discuss how these spatial biology platforms could support your research, feel free to reach out!”
Quoting The National Institutes of Health‘s post:
”NEWS: An NIH clinical trial has shown promise for an experimental treatment for people with severe aplastic anemia, a life-threatening disorder with limited treatments.”
Read the full announcement here.
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 8, 2026, 13:26Akhil Santhosh: Closing the Gap in Chemotherapy-Induced Thrombocytopenia
-
Sep 8, 2026, 13:12Roman Rodionov: Is Lp(a) Another Homocysteine?
-
Sep 8, 2026, 12:48Denis Oduor: Beyond the Donation Chair and Into a Legacy of Hope
-
Sep 8, 2026, 12:24Alejandro González Veliz: Can a Stent Cause a Heart Attack?
-
Sep 8, 2026, 11:15Andreas Tridimas: Atherosclerosis Is Greyer Than We Admit
-
Sep 8, 2026, 10:59Eman M. Elsabbagh: Pediatric Nonmalignant HCT Enters the Era of Precision Conditioning and Gene Therapy
-
Sep 8, 2026, 10:50Dena Winchester: Sponsored Genetic Testing Programs Improve Access for Children With Hemophilia A
-
Sep 8, 2026, 10:49Alessandra Bosch: Von Willebrand Disease and Rare Bleeding Disorders, Collaborative Insights and Patient Empowerment
-
Sep 8, 2026, 09:42Vineet Sankhla: Rethinking Potent P2Y12 Inhibition in AF Patients Undergoing PCI